Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

71.86 +0.35 (+0.50%)
Streaming Delayed Price Updated: 11:51 AM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Arcellx, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Arcellx (ACLX) Q2 Revenue Drops 72%
Via The Motley Fool
4 Analysts Assess Arcellx: What You Need To Know
 
Via Benzinga
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers
FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment. 
Via Benzinga
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
(ACLX) - Analyzing Arcellx's Short Interest
 
Via Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Arcellx
 
Via Benzinga
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention
Gilead reported Q4 adjusted EPS of $1.90, exceeding estimates, with HIV sales up 16%. The company raised guidance and expects a key HIV drug launch in 2025. 
Via Benzinga
Arcellx Stock Earns 82 Relative Strength Rating
Arcellx stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 79 to 82. 
Via Investor's Business Daily
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
14 Analysts Have This To Say About Arcellx
 
Via Benzinga
Analyst Expectations For Arcellx's Future
 
Via Benzinga
Navigating 7 Analyst Ratings For Arcellx
 
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Arcellx
 
Via Benzinga
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes. 
Via Benzinga
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
4 Analysts Assess Arcellx: What You Need To Know
 
Via Benzinga
Assessing Arcellx: Insights From 7 Financial Analysts
 
Via Benzinga
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q2 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Decoding 8 Analyst Evaluations For Arcellx
 
Via Benzinga
The Latest Analyst Ratings For Arcellx
 
Via Benzinga
Expert Ratings For Arcellx
 
Via Benzinga
Analyst Expectations For Arcellx's Future
 
Via Benzinga
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
7 Biotech Stocks to Put on Your Breakthrough Radar
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
ACLX Stock Earnings: Arcellx Beats EPS, Beats Revenue for Q1 2024
ACLX stock results show that Arcellx beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
Peering Into Arcellx's Recent Short Interest
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.